Skip to main content
Erschienen in: Heart and Vessels 5/2013

01.09.2013 | Original Article

Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease

verfasst von: Toshiyuki Nagai, Takuro Hirano, Mayumi Tsunoda, Haruhiko Hosaka, Yoshikazu Kishino, Takaharu Katayama, Keisuke Matsumura, Takashi Miyagawa, Shun Kohsaka, Toshihisa Anzai, Keiichi Fukuda, Masahiro Suzuki

Erschienen in: Heart and Vessels | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Despite the positive impact of percutaneous coronary intervention (PCI) on reducing mortality, a small percentage of patients experience poor myocardial reperfusion following PCI. However, factors associated with no-reflow remain unclear. We investigated clinical factors associated with no-reflow following PCI for coronary artery disease (CAD). We retrospectively analyzed 1622 consecutive CAD patients who underwent PCI over a 5-year period at our institution. Patients were divided into two groups according to the presence (n = 31) or absence (n = 1591) of no-reflow, defined as Thrombolysis in Myocardial Infarction flow grade <3 after PCI. No significant differences in patient characteristics or PCI strategy were seen between the no-reflow and normal flow groups. The incidence of no-reflow was significantly lower in the left circumflex artery (LCx) than in the left anterior descending artery (LAD) (P = 0.0015), with no differences in characteristics or PCI strategy between these two target vessels. Multivariate analysis revealed that involvement of the LCx was an independent protective factor against no-reflow (odds ratio 0.14, 95 % confidence interval 0.02–0.98, P = 0.044). In conclusion, LCx as the target vessel was protective against no-reflow compared with LAD following PCI for CAD. Our results suggest that embolic protection devices may be unnecessary in CAD patients with involvement of LCx.
Literatur
1.
Zurück zum Zitat Jaffe R, Charron T, Puley G, Dick A, Strauss BH (2008) Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117:3152–3156PubMedCrossRef Jaffe R, Charron T, Puley G, Dick A, Strauss BH (2008) Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117:3152–3156PubMedCrossRef
3.
Zurück zum Zitat Butler M, Ajani A, Andrianopoulos N, Clarke D, Reid C, Shaw J, Brennan A, Lew R, Dart A, Duffy S (2008) Predictors and outcomes of the no-reflow phenomenon. Heart Lung Circ 17(Supplement 3):S176 Butler M, Ajani A, Andrianopoulos N, Clarke D, Reid C, Shaw J, Brennan A, Lew R, Dart A, Duffy S (2008) Predictors and outcomes of the no-reflow phenomenon. Heart Lung Circ 17(Supplement 3):S176
4.
Zurück zum Zitat Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS (1994) Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 89:2514–2518PubMedCrossRef Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS (1994) Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 89:2514–2518PubMedCrossRef
6.
Zurück zum Zitat Abbo KM, Dooris M, Glazier S, O’Neill WW, Byrd D, Grines CL, Safian RD (1995) Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 75:778–782PubMedCrossRef Abbo KM, Dooris M, Glazier S, O’Neill WW, Byrd D, Grines CL, Safian RD (1995) Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 75:778–782PubMedCrossRef
7.
Zurück zum Zitat Resnic FS, Wainstein M, Lee MKY, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CDK, Popma JJ, Piana R (2003) No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 145:42–46PubMedCrossRef Resnic FS, Wainstein M, Lee MKY, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CDK, Popma JJ, Piana R (2003) No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 145:42–46PubMedCrossRef
8.
Zurück zum Zitat Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schomig A, Kastrati A (2010) 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55:2383–2389PubMedCrossRef Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schomig A, Kastrati A (2010) 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55:2383–2389PubMedCrossRef
9.
Zurück zum Zitat Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O’Neill W, Grines CL (2003) Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 92:1445–1447PubMedCrossRef Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O’Neill W, Grines CL (2003) Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 92:1445–1447PubMedCrossRef
10.
Zurück zum Zitat Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ (2011) Management of the no-reflow phenomenon. Pharmacol Ther 132:72–85PubMedCrossRef Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ (2011) Management of the no-reflow phenomenon. Pharmacol Ther 132:72–85PubMedCrossRef
11.
Zurück zum Zitat Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR (2001) Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 37:1335–1343PubMedCrossRef Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR (2001) Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 37:1335–1343PubMedCrossRef
12.
Zurück zum Zitat Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G (2005) Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 95:1358–1361PubMedCrossRef Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G (2005) Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 95:1358–1361PubMedCrossRef
13.
Zurück zum Zitat Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, Saito H, Ujihira T (2011) Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels 26:379–384PubMedCrossRef Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, Saito H, Ujihira T (2011) Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels 26:379–384PubMedCrossRef
14.
Zurück zum Zitat Investigators E (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87–92CrossRef Investigators E (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87–92CrossRef
15.
Zurück zum Zitat Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, Gibson CM (2002) Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (vapor) trial. J Invasive Cardiol 14:299–302PubMed Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, Gibson CM (2002) Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (vapor) trial. J Invasive Cardiol 14:299–302PubMed
16.
Zurück zum Zitat Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O’Neill WW, Safian RD (1996) Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 39:113–118PubMedCrossRef Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O’Neill WW, Safian RD (1996) Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 39:113–118PubMedCrossRef
17.
Zurück zum Zitat Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, Fujita N, Sasaki S, Matsunaga T, Okumura K (2004) Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 148:E15PubMedCrossRef Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, Fujita N, Sasaki S, Matsunaga T, Okumura K (2004) Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 148:E15PubMedCrossRef
18.
Zurück zum Zitat Ishii H, Ichimiya S, Kanashiro M, Amano T, Matsubara T, Murohara T (2006) Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia. Diabetes Care 29:202–206PubMedCrossRef Ishii H, Ichimiya S, Kanashiro M, Amano T, Matsubara T, Murohara T (2006) Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia. Diabetes Care 29:202–206PubMedCrossRef
19.
Zurück zum Zitat Jaffe R, Dick A, Strauss BH (2010) Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv 3:695–704PubMedCrossRef Jaffe R, Dick A, Strauss BH (2010) Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv 3:695–704PubMedCrossRef
20.
Zurück zum Zitat Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, Mehran R (2005) Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293:1063–1072PubMedCrossRef Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, Mehran R (2005) Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293:1063–1072PubMedCrossRef
21.
Zurück zum Zitat Gick M, Jander N, Bestehorn HP, Kienzle RP, Ferenc M, Werner K, Comberg T, Peitz K, Zohlnhofer D, Bassignana V, Buettner HJ, Neumann FJ (2005) Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 112:1462–1469PubMedCrossRef Gick M, Jander N, Bestehorn HP, Kienzle RP, Ferenc M, Werner K, Comberg T, Peitz K, Zohlnhofer D, Bassignana V, Buettner HJ, Neumann FJ (2005) Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 112:1462–1469PubMedCrossRef
22.
Zurück zum Zitat Haeck JD, Koch KT, Bilodeau L, Van der Schaaf RJ, Henriques JP, Vis MM, Baan J Jr, Van der Wal AC, Piek JJ, Tijssen JG, Krucoff MW, De Winter RJ (2009) Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (Proximal Embolic Protection in Acute Myocardial Infarction and Resolution of ST-Elevation) study. JACC Cardiovasc Interv 2:934–943PubMedCrossRef Haeck JD, Koch KT, Bilodeau L, Van der Schaaf RJ, Henriques JP, Vis MM, Baan J Jr, Van der Wal AC, Piek JJ, Tijssen JG, Krucoff MW, De Winter RJ (2009) Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (Proximal Embolic Protection in Acute Myocardial Infarction and Resolution of ST-Elevation) study. JACC Cardiovasc Interv 2:934–943PubMedCrossRef
23.
Zurück zum Zitat Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, Mehilli J, Schomig A, Kastrati A (2010) Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 3:27–33PubMedCrossRef Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, Mehilli J, Schomig A, Kastrati A (2010) Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 3:27–33PubMedCrossRef
24.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252PubMedCrossRef
25.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRef
26.
Zurück zum Zitat Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
27.
Zurück zum Zitat Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254PubMedCrossRef Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254PubMedCrossRef
28.
Zurück zum Zitat Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50PubMedCrossRef Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50PubMedCrossRef
29.
Zurück zum Zitat Ito H (2006) No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3:499–506PubMedCrossRef Ito H (2006) No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3:499–506PubMedCrossRef
30.
Zurück zum Zitat Kondo M, Nakano A, Saito D, Shimono Y (1998) Assessment of “Microvascular no-reflow phenomenon” Using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 32:898–903PubMedCrossRef Kondo M, Nakano A, Saito D, Shimono Y (1998) Assessment of “Microvascular no-reflow phenomenon” Using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 32:898–903PubMedCrossRef
31.
Zurück zum Zitat Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, Nagata S, Hori M (2002) Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 106:1672–1677PubMedCrossRef Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, Nagata S, Hori M (2002) Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 106:1672–1677PubMedCrossRef
32.
Zurück zum Zitat Seong MM Jr, Kim KS, Kim B-k, Son j-y, Hong S-p, Lee YS, Lee JB, Ryu JK, Choi JY, Chang S-G (2011) Predictors of no-reflow phenomenon during primary PCI in STEMI patients. J Am Coll Cardiol 57:E942 Seong MM Jr, Kim KS, Kim B-k, Son j-y, Hong S-p, Lee YS, Lee JB, Ryu JK, Choi JY, Chang S-G (2011) Predictors of no-reflow phenomenon during primary PCI in STEMI patients. J Am Coll Cardiol 57:E942
33.
Zurück zum Zitat Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, Lee SE, Kim SH, Park KH, Sim DS, Yoon NS, Youn HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC (2009) Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction. J Cardiol 54:36–44PubMedCrossRef Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, Lee SE, Kim SH, Park KH, Sim DS, Yoon NS, Youn HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC (2009) Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction. J Cardiol 54:36–44PubMedCrossRef
34.
Zurück zum Zitat Chen Y, Wang C, Yang X, Wang L, Sun Z, Liu H, Chen L (2012) Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Heart Vessels 27:243–249PubMedCrossRef Chen Y, Wang C, Yang X, Wang L, Sun Z, Liu H, Chen L (2012) Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Heart Vessels 27:243–249PubMedCrossRef
35.
Zurück zum Zitat Tanaka A, Kawarabayashi T, Nishibori Y, Sano T, Nishida Y, Fukuda D, Shimada K, Yoshikawa J (2002) No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105:2148–2152PubMedCrossRef Tanaka A, Kawarabayashi T, Nishibori Y, Sano T, Nishida Y, Fukuda D, Shimada K, Yoshikawa J (2002) No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105:2148–2152PubMedCrossRef
36.
Zurück zum Zitat Kotani J, Mintz GS, Pregowski J, Kalinczuk L, Pichard AD, Satler LF, Suddath WO, Waksman R, Weissman NJ (2003) Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 92:728–732PubMedCrossRef Kotani J, Mintz GS, Pregowski J, Kalinczuk L, Pichard AD, Satler LF, Suddath WO, Waksman R, Weissman NJ (2003) Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 92:728–732PubMedCrossRef
37.
Zurück zum Zitat Mizote I, Ueda Y, Ohtani T, Shimizu M, Takeda Y, Oka T, Tsujimoto M, Hirayama A, Hori M, Kodama K (2005) Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angioscopically defined ruptured plaque. Circulation 112:1001–1007PubMedCrossRef Mizote I, Ueda Y, Ohtani T, Shimizu M, Takeda Y, Oka T, Tsujimoto M, Hirayama A, Hori M, Kodama K (2005) Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angioscopically defined ruptured plaque. Circulation 112:1001–1007PubMedCrossRef
38.
Zurück zum Zitat Niccoli G, Burzotta F, Galiuto L, Crea F (2009) Myocardial no-reflow in humans. J Am Coll Cardiol 54:281–292PubMedCrossRef Niccoli G, Burzotta F, Galiuto L, Crea F (2009) Myocardial no-reflow in humans. J Am Coll Cardiol 54:281–292PubMedCrossRef
Metadaten
Titel
Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease
verfasst von
Toshiyuki Nagai
Takuro Hirano
Mayumi Tsunoda
Haruhiko Hosaka
Yoshikazu Kishino
Takaharu Katayama
Keisuke Matsumura
Takashi Miyagawa
Shun Kohsaka
Toshihisa Anzai
Keiichi Fukuda
Masahiro Suzuki
Publikationsdatum
01.09.2013
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 5/2013
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-012-0281-2

Weitere Artikel der Ausgabe 5/2013

Heart and Vessels 5/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.